Abbott Laboratories ($ABT) Stock Forecast: Down 8.0% Today

What is Abbott Laboratories?

Abbott Laboratories (NYSE: ABT) is a healthcare company that specializes in the development and manufacturing of medical devices, diagnostics, and nutrition products. The company has demonstrated resilience and growth over the past year.

Why is Abbott Laboratories going down?

ABT stock is down 8.0% on Jul 17, 2025 18:35

• ABT stock faced a notable decline today, with a decrease of 8.07%.
• The company's third-quarter earnings projection, which fell below analyst expectations, is believed to have played a role in the significant drop in the stock price.
• Investors' reaction to the adjusted earnings outlook likely triggered a sell-off of ABT shares during the pre-market trading session.
• Heightened market sensitivity ahead of the upcoming second-quarter earnings release may have prompted investors to reposition themselves based on the revised forecasts.

ABT Price Chart

ABT Technical Analysis

ABT News

P/E Ratio Insights for Abbott Laboratories - Abbott Laboratories ( NYSE:ABT )

Looking into the current session, Abbott Laboratories Inc. ABT shares are trading at $121.11, after a 8.07% drop. Over the past month, the stock fell by 8.93%, but over the past year, it actually went up by 18.71%.

https://www.benzinga.com/insights/news/25/07/46476673/pe-ratio-insights-for-abbott-laboratories

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Abbott Laboratories ( NYSE:ABT ) , Guess ( NYSE:GES )

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday. Shares of Abbott Laboratories ABT fell sharply in pre-market trading after the company issued third-quarter adjusted EPS guidance below estimates.

https://www.benzinga.com/trading-ideas/movers/25/07/46465221/abbott-laboratories-issues-weak-earnings-forecast-joins-mp-materials-and-other-big-stocks-mo

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Abbott Laboratories ( NYSE:ABT )

Abbott Laboratories ABT will release earnings results for the second quarter, before the opening bell on Thursday, July 17. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.25 per share, up from $1.14 per share in the year-ago period.

https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46447307/abbott-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahe

Trending Today

Litecoin ($LTC) Crypto Forecast: Up 5.5% Today

Chainlink ($LINK) Crypto Forecast: Up 5.2% Today

XRP ($XRP) Crypto Forecast: Up 12.8% Today

Stellar ($XLM) Crypto Forecast: Up 7.4% Today

Elevance Health Inc. ($ELV) Stock Forecast: Down 12.9% Today

PepsiCo Inc. ($PEP) Stock Forecast: Up 7.8% Today

Abbott Laboratories ($ABT) Stock Forecast: Down 8.0% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 5.2% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 20.1% Today

Snap-On Incorporated ($SNA) Stock Forecast: Up 6.1% Today

Abbott Laboratories Price History

17.06.2025 - ABT Stock was down 8.0%

• ABT stock faced a notable decline today, with a decrease of 8.07%.
• The company's third-quarter earnings projection, which fell below analyst expectations, is believed to have played a role in the significant drop in the stock price.
• Investors' reaction to the adjusted earnings outlook likely triggered a sell-off of ABT shares during the pre-market trading session.
• Heightened market sensitivity ahead of the upcoming second-quarter earnings release may have prompted investors to reposition themselves based on the revised forecasts.

16.09.2024 - ABT Stock was down 0.1%

• Despite strong Q3 earnings surpassing expectations, ABT's stock saw a bearish trend today.
• The market reaction may have been influenced by mixed U.S. stock futures trading, impacting investor sentiment towards healthcare stocks like ABT.
• Today’s 2.26% decline in stock price could be due to profit-taking by investors following a period of consistent growth.
• While ABT remains on track to meet its annual forecast, short-term market movements and overall market conditions likely played a role in today's bearish performance.

02.04.2025 - ABT Stock was up 2.8%

• ABT's stock price surged by 0.40% during the current market session, signaling strong bullish momentum.
• Despite a minor decline in the last month, the stock has notably jumped by 22.07% over the past year, reflecting promising long-term growth prospects.
• The optimistic momentum can be attributed to favorable market conditions, potential advancements in the healthcare industry, or a positive earnings outlook for the company.

07.05.2024 - ABT Stock was up 1.3%

• ABT stock experienced a bullish movement today, likely driven by multiple factors:
• The positive outlook on dividend-paying companies in the current market environment could have attracted investors to ABT due to its strong dividend track record.
• The average brokerage recommendation of 1.50 for ABT, indicating a Strong Buy sentiment from analysts, might have boosted investor confidence in the stock.
• The technical issues leading to trading halts for NYSE stocks, including ABT, could have created volatility in the market, potentially leading to increased trading activity in ABT as investors sought stability in healthcare stocks.
• Overall, the combination of positive market sentiment towards dividend stocks, favorable analyst recommendations, and technical issues impacting trading on the NYSE likely contributed to ABT's bullish movement today.

16.03.2025 - ABT Stock was up 5.4%

• Abbott Laboratories reported positive Q1 earnings, with sales increasing by 7.2% and adjusted EPS surpassing consensus estimates, potentially influencing the uptick in ABT stock.
• The company's strong performance in the Medical Device segment, notably with products like FreeStyle Libre and heart-related devices, demonstrated its resilience in uncertain times and its ability to drive growth.
• The purchase of a substantial amount of ABT stock by a member of the House of Representatives might have boosted investor confidence in the company's future, leading to increased buying activity and pushing the stock price up.
• Despite the overall market decline witnessed today, Abbott Laboratories' robust financial results, favorable market sentiment, and strategic growth initiatives likely propelled the bullish trend in ABT stock.

11.09.2023 - ABT Stock was down 1.9%

• The bearish movement in ABT's stock today could be attributed to the following factors:
• 1. Negative sentiment from Jim Cramer: Jim Cramer, a well-known financial commentator, expressed his concerns about the company due to Elon Musk's comment about not liking the business. This might have caused some investors to sell their shares, leading to a bearish market movement.
• 2. Increase in stake by Moody Lynn & Lieberson LLC: Despite the overall bearish movement, Moody Lynn & Lieberson LLC increased its stake in ABT during the second quarter. This suggests that there might be some positive long-term prospects for the company, which could potentially counterbalance the short-term bearish sentiment.
• 3. Overall market conditions: It's important to consider the broader market conditions when analyzing the movement of a specific stock. If the overall market experienced a bearish trend today, it could have influenced ABT's stock as well, regardless of the company's specific news or events.
• In conclusion, the bearish movement in ABT's stock today could be attributed to negative sentiment from Jim Cramer and potentially influenced by the overall market conditions. However, the increase in stake by Moody Lynn & Lieberson LLC indicates some positive long-term prospects for the company.

11.09.2023 - ABT Stock was down 5.2%

• The bearish movement in ABT's stock today could be attributed to the following factors:
• 1. Market shift: Abbott Laboratories is exploring the consumer wearables market as COVID testing sales dwindle. This strategic move might have raised concerns among investors about the company's focus and potential impact on its financial performance.
• 2. Elon Musk's influence: Jim Cramer mentioned on CNBC's "Mad Money" that he is a seller of ABT because Elon Musk stated that he doesn't like that business. Musk's negative sentiment towards the company could have influenced investor sentiment and contributed to the bearish movement.
• 3. Stake increase: Moody Lynn & Lieberson LLC increased its stake in Abbott Laboratories, indicating confidence in the company. However, this positive development might not have been enough to counterbalance other factors affecting the stock's movement.
• 4. Overall market conditions: The bearish movement in ABT's stock could also be a result of broader market trends or sector-specific factors impacting healthcare stocks. It's important to consider the overall market conditions when assessing individual stock movements.

20.01.2024 - ABT Stock was up 1.9%

• Several factors may have contributed to the bullish movement in ABT stock:
• Abbott Laboratories announced a $0.55 dividend, which could have attracted income-seeking investors, thereby increasing the stock's appeal.
• The FDA's Circulatory System Devices Panel provided a favorable recommendation for Abbott's Minimally Invasive Heart Valve Repair Device, the TriClip system, potentially boosting investor confidence in the company's medical innovations.
• An FDA independent panel endorsed the safety profile of Abbott's heart device TriClip, showcasing the company's dedication to pioneering healthcare solutions. This news likely fueled investor confidence and drove the stock price up.

15.02.2024 - ABT Stock was down 5.4%

• ABT stock experienced a bearish trend today possibly due to profit-taking by investors following a period of strong performance.
• Analysts have pointed to discussions on growth in the in-vitro diagnostics market and Roche's AI-based glucose monitoring system launch as factors diverting attention from ABT momentarily.
• The overall optimism in the healthcare industry, exemplified by the Medical Devices ETF reaching a 52-week peak, may have prompted some investors to adjust their portfolios within the sector, impacting ABT's stock performance.
• ABT's sustained outperformance over time, as alluded to by market observations, suggests that today's bearish movement could be a brief correction in the context of the company's favorable long-term trajectory.

08.07.2023 - ABT Stock was down 2.8%

• The bearish movement in ABT today might be attributed to the following factors:
• 1. Options activity: The presence of a large bearish position in ABT options suggests that someone with a significant amount of money has taken a negative stance on the stock. This could have influenced market sentiment and contributed to the bearish movement.
• 2. Dividend considerations: While there is positive sentiment surrounding ABT's dividend, it is possible that some investors are focusing on other aspects of the company's performance, leading to a bearish outlook.
• 3. Comparison with AbbVie: The comparison between Abbott Laboratories and AbbVie, particularly in terms of investment potential, might have influenced market perception. If investors perceive AbbVie as a better investment choice, it could have negatively impacted ABT's stock price.
• Overall, the bearish movement in ABT today could be influenced by options activity, dividend considerations, and comparisons with other companies in the healthcare sector.

18.06.2024 - ABT Stock was down 1.2%

• Despite reporting strong Q2 earnings with EPS beating estimates, Abbott Laboratories (ABT) experienced a bearish movement in its stock.
• The market may have reacted negatively to a slight revenue miss, even though the full-year guidance was raised, indicating potential concerns about future performance.
• Investors might have been expecting higher revenue growth, leading to profit-taking and a bearish trend in the stock price.
• Market sentiment could have been influenced by broader economic conditions or global events, overshadowing the positive earnings beat.

17.06.2025 - ABT Stock was down 6.3%

• A weak earnings projection for the third quarter by Abbott Laboratories, falling below market expectations, caused a significant drop in the stock's value.
• Analysts, who had adjusted their predictions prior to the earnings announcement, were anticipating an uptick in quarterly earnings per share. The unexpected weaker guidance likely surprised investors, contributing to the bearish trend.
• The general pessimism towards ABT was magnified by the overall downtrend in U.S. stock futures, with the Dow futures declining by around 0.2% on the same day.